Treatment for glioblastoma

A method for treating a glioblastoma in a human or animal subject comprising the steps of:

• identifying the human or animal subject in need of treatment of a glioblastoma, wherein the human or animal is no longer responsive to at least one of chemotherapy, surgery, or radiation therapy;
• and
• administering to the human or animal subject a therapeutically effective amount of a composition comprising:
• an amount of a curcumin or curcuminoids in one or more liposomes, or curcumin or curcuminoids and empty liposomes and administered prior to, concomitantly, or after administration of the curcumin or curcuminoids, that is effective for treating the glioblastoma, wherein the liposomal curcumin or curcuminoids, or empty liposomes, eliminate the QT prolongation caused by the curcumin or curcuminoids;
• and
• at least one chemotherapeutic agent that is synergistic with curcumin to treat the glioblastoma, selected from at least one of temozolomide, etoposide, doxorubicin, cisplatin, paclitaxel, carmustine, lomustine, ceramide and phosphorylcholine.

A method of determining the effectiveness of a candidate drug that is a chemotherapeutic agent that sensitizes or synergizes with curcumin to treat the glioblastoma, the method comprising:

• measuring the effect of a candidate agent on a glioblastoma cell;
• administering the candidate drug to a first subset of glioblastoma cells, and a combination of the candidate drug with curcumin to a second subset of glioblastoma cells;
• and
• determining if the curcumin sensitizes or synergizes the glioblastoma cells to the candidate agent in the first versus the second subset of glioblastoma cells.